
PPAR
Peroxisome Proliferator-Activated Receptors (PPARs) are a group of nuclear receptor proteins that function as transcription factors regulating the expression of genes involved in metabolism, particularly fatty acid storage and glucose metabolism. PPAR inhibitors are important tools for studying metabolic disorders such as diabetes, obesity, and cardiovascular diseases. These inhibitors can modulate lipid metabolism, insulin sensitivity, and inflammation, making them valuable in therapeutic research. At CymitQuimica, we offer a range of PPAR inhibitors to support your research in metabolic diseases, endocrinology, and drug development.
Found 164 products of "PPAR"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Edaglitazone
CAS:<p>Edaglitazone (R-483) is a PPARγ agonist with antiplatelet activity that can be used in studies of diabetes and obesity.</p>Formula:C24H20N2O4S2Purity:98%Color and Shape:SolidMolecular weight:464.56LCB-2853
CAS:<p>LCB-2853 is a potent thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptor antagonist with antiplatelet aggregation, antivasospasm, and antithrombotic effects.</p>Formula:C21H24ClNO4SPurity:97.15%Color and Shape:SolidMolecular weight:421.94Imiglitazar
CAS:<p>Imiglitazar (TAK559) is a potent PPAR-β/δ receptor agonist with hypoglycemic effects.</p>Formula:C28H26N2O5Purity:97.33%Color and Shape:SolidMolecular weight:470.52PPAR agonist 1
CAS:<p>PPAR agonist 1 is an agonist of PPAR α/γ, used for reducing blood glucose, lipid levels, reducing body weight, and lowering cholesterol.</p>Formula:C20H25NO6SPurity:98%Color and Shape:SolidMolecular weight:407.48U-46619
CAS:<p>U-46619 is an effective thromboxane A2 (TXA2) agonist and a thromboxane A2 analog (endoperoxide), capable of inducing contraction in the aortic smooth muscle (</p>Formula:C21H34O4Purity:98%Color and Shape:SolidMolecular weight:350.49KD-3010
CAS:<p>KD-3010 (Kalypsys) is an orally active potent and selective PPARδ agonist for the study of liver injury.</p>Formula:C30H33F3N2O8S2Purity:99.61%Color and Shape:SolidMolecular weight:670.72CRX000227
CAS:<p>CRX000227 is a PPAR modulator suitable for researching metabolic and cell proliferative disorders [1].</p>Formula:C25H24N4O2SPurity:98%Color and Shape:SolidMolecular weight:444.55PPARγ agonist 8
CAS:<p>PPARγ agonist 8, a compound that acts on the peroxisome proliferator-activated receptor gamma (PPARγ), has been shown to stimulate peroxisome proliferator</p>Formula:C19H12F4O2SPurity:98%Color and Shape:SolidMolecular weight:380.36Darglitazone
CAS:<p>Darglitazone (CP-86325) is a potent, selective agonist of PPAR-γ with antidiabetic actions.</p>Formula:C23H20N2O4SPurity:99.76%Color and Shape:SolidMolecular weight:420.48PPARδ agonist 9
CAS:<p>PPARδ agonist 9 (compound 21), with an EC50 of 3.6 nM, is effective in vivo, decreasing serum MCP-1 concentrations in mice and markedly reducing atherosclerotic</p>Formula:C26H28ClF3N4O3SPurity:98%Color and Shape:SolidMolecular weight:569.04Ragaglitazar
CAS:<p>Ragaglitazar(NNC-61-0029) is a potent dual activator of PPARγ and PPARα.Cost-effective and quality-assured.</p>Formula:C25H25NO5Purity:97.46% - 98.56%Color and Shape:SolidMolecular weight:419.47Inolitazone
CAS:<p>Inolitazone (RS5444) a high-affinity PPARγ agonist. Inolitazone exhibits IC50 for growth inhibition is ~0.8 nM in vitro.</p>Formula:C27H26N4O4SPurity:99.41% - 99.53%Color and Shape:SolidMolecular weight:502.58Fonadelpar
CAS:<p>Fonadelpar is an agonist of PPARδ. It also is used in the research of neuroparalytic keratopathy.</p>Formula:C25H23F3N2O4SPurity:98%Color and Shape:SolidMolecular weight:504.52Anti-NASH agent 2
CAS:<p>Anti-NASH agent 2 (compound 21) is an inhibitor of neolipogenesis activity and α-SMA gene expression. It improves hepatic steatosis, edema, inflammatory infiltration, and liver fibrosis in NASH mouse models.</p>Formula:C32H51N3O2Color and Shape:SolidMolecular weight:509.766PPARγ agonist 17
CAS:<p>PPARγ agonist17 (Compound C1) is an orally active PPARγ agonist. It enhances PPARγ activity, arrests the cell cycle of HT-29 cells at the G2/M phase, inhibits cell migration, and induces apoptosis. PPARγ agonist17 exhibits broad-spectrum antiproliferative activity against cancer cells with relatively low toxicity to normal cells and does not cross the blood-brain barrier.</p>Formula:C48H63NO7Color and Shape:SolidMolecular weight:766.016PPARγ modulator-2
CAS:<p>PPARγmodulator-2 (Compound (R)-2n) is a reversible modulator of PPARγ, inhibiting the PPARγ ligand-binding domain (LBD) with an IC50 of 41 nM. It helps lower blood glucose levels, improves glucose tolerance and insulin sensitivity, and demonstrates antidiabetic activity in db/db mouse models.</p>Formula:C26H21NO7S3SeColor and Shape:SolidMolecular weight:634.6Amezalpat
CAS:<p>Amezalpat is a PPARα antagonist with an IC50 of 58 nM [nanomolar]. Amezalpat also exhibits antitumor activity.</p>Formula:C34H41N3O4Color and Shape:SolidMolecular weight:555.707PPARγ-IN-5
CAS:<p>PPARγ-IN-5 (Compound A3) is an inhibitor of PPARγ. In liver cells, it reduces lipid accumulation and shows no significant cytotoxicity in HepG2 cells at a concentration of 400 µM. PPARγ-IN-5 is applicable for research on non-alcoholic fatty liver disease.</p>Formula:C22H23ClO7Color and Shape:SolidMolecular weight:434.867PPARα/δ agonist 3
CAS:<p>PPARα/δ agonist 3 (Compound 8) is an orally active PPAR agonist capable of activating PPARα, PPARδ, and PPARγ, with EC50 values of 5.6 nM, 3.4 nM, and 1278 nM, respectively. It exhibits anti-cholestatic activity in mouse models of cholestatic liver disease induced by ANIT or CDCA.</p>Formula:C23H25F3N2O4Color and Shape:SolidMolecular weight:450.451PPARδ agonist 11
CAS:<p>Compound 11, a selective PPARδ agonist, demonstrates an EC50 of 20 nM, indicating its high affinity for PPARδ receptors. This compound efficiently reduces levels of nitric oxide (NO), as well as the pro-inflammatory cytokines TNFα and IL-6 in LPS-stimulated RAW264.7 cells via the NF-κB pathway, showcasing its anti-inflammatory properties. Additionally, Compound 11 exhibits remarkable stability in human liver microsomes and plasma. It significantly ameliorates foot edema induced by Carrageenan, displaying favorable pharmacokinetic properties with a bioavailability of approximately 100%.</p>Formula:C19H15F3N2O3S2Color and Shape:SolidMolecular weight:440.46
